Skip to main content
Premium Trial:

Request an Annual Quote

New Product Watch: Oct 25, 2011

Premium

Microarrays Inc. this week launched three MI PathArray assays for studying targeted biological pathways. The new arrays cover pathways associated with apoptosis, growth factors, and inflammation. Each slide contains four subarrays with an average coverage of three probes per gene plus controls and probes for data normalization. On its website, MI says it plans to introduce arrays for studying cancer and transcription factors in the future. The company also plans to eventually sell kits and hardware for sample preparation, processing, and array hybridization.

BioArray News spoke with CEO Joel Peek about the new offering earlier this month (BAN 10/11/11).

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.